CELC · All filings · Read this filing
What changed 10-Q
Item 2. Unregistered Sales of Equity Securities
2021-05-10 compared with 2020-11-09 · 1 added, 1 removed, 19 unchanged (10% of the section changed)
11 unchanged sentences
There has been no material change in the planned use of proceeds as described in our Prospectus filed with the SEC on September 20, 2017.
−Removed: From the Effective Date through September 30, 2020, we have used approximately $10.1 million in furtherance of our planned use of proceeds, which includes funding additional research and development for discovery of new cancer sub-types and development and validation of new CELsignia tests;
+Added: From the Effective Date through March 31, 2021, we have used approximately $14.8 million in furtherance of our planned use of proceeds, which includes funding additional research and development for discovery of new cancer sub-types and development and validation of new CELsignia tests;
clinical trials to support clinical claims;
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.